# A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver

> **NCT00441376** · PHASE1 · COMPLETED · sponsor: **Imunon** · enrollment: 30 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Liver Neoplasms

## Interventions

- **DRUG:** ThermoDox

## Key facts

- **NCT ID:** NCT00441376
- **Lead sponsor:** Imunon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2008-10
- **Final completion:** 2009-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441376, "A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00441376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*